Under construction – not a live service
Sign in
Not yet taking people in CanadaNo phase

Following adults with high red blood cell counts over time

Observes adults with elevated hemoglobin to study diagnosis, care and long-term outcomes.

Plain-language title generated from the registry record
Registry title: EVAluation of Erythrocytosis PRospEctive Cohort STudy

Key facts

Where
London, CanadaSee the site

Where in Canada

  • Victoria Hospital, London Health Sciences CentreLondon, CanadaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Cyrus Hsia
Trial code
NCT06785870
Record updated
21 January 2025
Original description
The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin (erythrocytosis). This longitudinal, prospective study will generate high quality data that can help inform the optimal approach to diagnosis and management in this patient population.Read full original descriptionShow less

Evaluation of Erythrocytosis Prospective Cohort Study (EVEREST): Diagnosis, Management and Longitudinal Outcomes in Patients with Elevated Hemoglobin

The EValuation of ERythrocytosis pRospEctive cohort STudy (EVEREST) is a prospective study designed to shed light on these key questions in the diagnosis, management, and clinical outcomes in patients with elevated hemoglobin (erythrocytosis). This longitudinal, prospective study will generate high quality data that can help inform the optimal approach to diagnosis and management in this patient population.

Inclusion: Adult patients (>=18 years) referred to hematology clinics at London Health Sciences Centre with hemoglobin levels >=165 g/L in males or >=160 g/L in females; Patients capable of providing informed consent; Age >= 18 years.

Exclusion: Patients <18 years; Patients without erythrocytosis; Patients incapable of providing informed consent.

ClinicalTrials.gov NCT06785870